| Melissa B Roberts, MD | |
|
5001 Hardy St, Hattiesburg, MS 39402-1308 | |
| (601) 268-8000 | |
| Not Available |
| Full Name | Melissa B Roberts |
|---|---|
| Gender | Female |
| Speciality | Emergency Medicine |
| Experience | 27 Years |
| Location | 5001 Hardy St, Hattiesburg, Mississippi |
| Accepts Medicare Assignments | May be. She may accept the Medicare-approved amount; you may be billed for more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1174517007 | NPI | - | NPPES |
| 00123317 | Medicaid | MS |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207PE0004X | Emergency Medicine - Emergency Medical Services | 15983 (Mississippi) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| George Regional Health System | Lucedale, MS | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| George Regional Er Physicians | 6608180138 | 7 |
News Archive
Orexigen® Therapeutics, Inc., a biopharmaceutical company focused on the treatment of obesity, today announced that the U.S. Food and Drug Administration has assigned a Prescription Drug User Fee Act (PDUFA) action date of January 31, 2011 for the review of the Contrave® (naltrexone sustained release (SR)/bupropion SR) New Drug Application (NDA).
"The Obama administration on Thursday released a sweeping statement of its national security goals," the Los Angeles Times reports. The 52-page document "calls for the United States to strengthen international institutions, to heed treaties and norms, and to build stronger ties to allies, including to the emerging powers of India, Brazil and China.
New research conducted at the Florida State University-based National High Magnetic Field Laboratory has revealed a new, innovative way to classify the severity of a stroke, aid in diagnosis and evaluate potential treatments.
Decision Resources Group finds that the market for colorectal cancer (CRC) therapies will remain constant, at around $7.7 billion by 2023 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.
A UT Southwestern study is challenging concerns that a federal health policy enacted in 2012 to reduce hospital readmissions leaves patients more vulnerable.
› Verified 5 days ago
| Entity Name | George County Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1023074028 PECOS PAC ID: 5294717013 Enrollment ID: O20040604000732 |
News Archive
Orexigen® Therapeutics, Inc., a biopharmaceutical company focused on the treatment of obesity, today announced that the U.S. Food and Drug Administration has assigned a Prescription Drug User Fee Act (PDUFA) action date of January 31, 2011 for the review of the Contrave® (naltrexone sustained release (SR)/bupropion SR) New Drug Application (NDA).
"The Obama administration on Thursday released a sweeping statement of its national security goals," the Los Angeles Times reports. The 52-page document "calls for the United States to strengthen international institutions, to heed treaties and norms, and to build stronger ties to allies, including to the emerging powers of India, Brazil and China.
New research conducted at the Florida State University-based National High Magnetic Field Laboratory has revealed a new, innovative way to classify the severity of a stroke, aid in diagnosis and evaluate potential treatments.
Decision Resources Group finds that the market for colorectal cancer (CRC) therapies will remain constant, at around $7.7 billion by 2023 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.
A UT Southwestern study is challenging concerns that a federal health policy enacted in 2012 to reduce hospital readmissions leaves patients more vulnerable.
› Verified 5 days ago
| Entity Name | Community Medical Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1194734913 PECOS PAC ID: 8921072588 Enrollment ID: O20040820000647 |
News Archive
Orexigen® Therapeutics, Inc., a biopharmaceutical company focused on the treatment of obesity, today announced that the U.S. Food and Drug Administration has assigned a Prescription Drug User Fee Act (PDUFA) action date of January 31, 2011 for the review of the Contrave® (naltrexone sustained release (SR)/bupropion SR) New Drug Application (NDA).
"The Obama administration on Thursday released a sweeping statement of its national security goals," the Los Angeles Times reports. The 52-page document "calls for the United States to strengthen international institutions, to heed treaties and norms, and to build stronger ties to allies, including to the emerging powers of India, Brazil and China.
New research conducted at the Florida State University-based National High Magnetic Field Laboratory has revealed a new, innovative way to classify the severity of a stroke, aid in diagnosis and evaluate potential treatments.
Decision Resources Group finds that the market for colorectal cancer (CRC) therapies will remain constant, at around $7.7 billion by 2023 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.
A UT Southwestern study is challenging concerns that a federal health policy enacted in 2012 to reduce hospital readmissions leaves patients more vulnerable.
› Verified 5 days ago
| Entity Name | George Regional Er Physicians |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1043690936 PECOS PAC ID: 6608180138 Enrollment ID: O20150728006195 |
News Archive
Orexigen® Therapeutics, Inc., a biopharmaceutical company focused on the treatment of obesity, today announced that the U.S. Food and Drug Administration has assigned a Prescription Drug User Fee Act (PDUFA) action date of January 31, 2011 for the review of the Contrave® (naltrexone sustained release (SR)/bupropion SR) New Drug Application (NDA).
"The Obama administration on Thursday released a sweeping statement of its national security goals," the Los Angeles Times reports. The 52-page document "calls for the United States to strengthen international institutions, to heed treaties and norms, and to build stronger ties to allies, including to the emerging powers of India, Brazil and China.
New research conducted at the Florida State University-based National High Magnetic Field Laboratory has revealed a new, innovative way to classify the severity of a stroke, aid in diagnosis and evaluate potential treatments.
Decision Resources Group finds that the market for colorectal cancer (CRC) therapies will remain constant, at around $7.7 billion by 2023 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.
A UT Southwestern study is challenging concerns that a federal health policy enacted in 2012 to reduce hospital readmissions leaves patients more vulnerable.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Melissa B Roberts, MD Po Box 22505, Jackson, MS 39225-2505 Ph: (866) 321-8433 | Melissa B Roberts, MD 5001 Hardy St, Hattiesburg, MS 39402-1308 Ph: (601) 268-8000 |
News Archive
Orexigen® Therapeutics, Inc., a biopharmaceutical company focused on the treatment of obesity, today announced that the U.S. Food and Drug Administration has assigned a Prescription Drug User Fee Act (PDUFA) action date of January 31, 2011 for the review of the Contrave® (naltrexone sustained release (SR)/bupropion SR) New Drug Application (NDA).
"The Obama administration on Thursday released a sweeping statement of its national security goals," the Los Angeles Times reports. The 52-page document "calls for the United States to strengthen international institutions, to heed treaties and norms, and to build stronger ties to allies, including to the emerging powers of India, Brazil and China.
New research conducted at the Florida State University-based National High Magnetic Field Laboratory has revealed a new, innovative way to classify the severity of a stroke, aid in diagnosis and evaluate potential treatments.
Decision Resources Group finds that the market for colorectal cancer (CRC) therapies will remain constant, at around $7.7 billion by 2023 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.
A UT Southwestern study is challenging concerns that a federal health policy enacted in 2012 to reduce hospital readmissions leaves patients more vulnerable.
› Verified 5 days ago
Bradley Williams, DO Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 5001 Hardy St, Hattiesburg, MS 39402 Phone: 601-296-3963 | |
Miju Yu Kurtzweil, D.O. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 5001 Hardy St, Merit Health Wesley, Hattiesburg, MS 39402 Phone: 601-296-3963 | |
Dr. Carl Edward Johns Iii, DO Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 5001 Hardy St, Hattiesburg, MS 39402 Phone: 601-296-3963 | |
Robert C Owen, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 6051 Highway 49, Hattiesburg, MS 39401 Phone: 601-288-7000 | |
Trent Woods, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 6051 Highway 49, Hattiesburg, MS 39401 Phone: 601-288-7000 | |
Jacob Robert Fenster, Emergency Medicine Medicare: May Accept Medicare Assignments Practice Location: 5001 Hardy St, Hattiesburg, MS 39402 Phone: 601-296-3963 | |
Julie Marie Butler, ATC Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 118 College Dr, Hattiesburg, MS 39406 Phone: 601-268-5017 |